Clinical Trial Update: Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively [Phase 3]

View source ↗

Summary

Phase 3 trials are evaluating the safety and effectiveness of Giroctocogene Fitelparvovec for Hemophilia A and Fidanacogene Elaparvovec for Hemophilia B. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Fidanacogene Elaparvovec (fidanacogene elaparvovec)
• Giroctocogene Fitelparvovec (giroctocogene fitelparvovec)

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A, Hemophilia B | Phase 3 | Status: RECRUITING